Synthetopes, Inc., Conway, SC

Is Synthetopes, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Synthetopes, Inc. hold a South Carolina pharmacy license?

State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 6902 for Synthetopes, Inc., Conway, SC, status Voluntary Surrender, as of Nov 15, 2026.

Has Synthetopes, Inc. had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (May 16, 2019) for Synthetopes, Inc. State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026. The Colorado State Board of Pharmacy’s license dataset also lists “CLS Voluntary Surrender/Relinquishment” dated Aug 27, 2019, case 2019-2733 on nonresident license OSP 6902.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Synthetopes, Inc.
Location
Conway, SC
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 16, 2019
FDA Data Dashboard inspections
1 inspection: 1 OAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 8 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Synthetopes, Inc., a 503A facility, with 1 dated action.

Document
May 16, 2019Form 483483 Issued 05/16/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Synthetopes Inc, Conway, SC (FEI number 3007488106), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 16, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30074881061089726

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 6, 2019 to May 16, 2019: 8 observations

Firm on the cover
Synthetopes Inc, 216 Earnhardt St, Conway, SC 29526-8287
FEI number
3007488106
Establishment type on the cover
Producer of Sterile Drugs
FDA district office on the cover
555 Winderley Place, Suit e 200 Mait land, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Each batch of drug product purpoiting to be sterile is not laboratory tested to determine conformance to such requirements.

Specifically, your Pharmacist stated that no sterility testing is conducted for the following radiological and nuclear injectable drug products:

a. Dimercaptosuccinic Acid (DMSA) kits, 1.09mg <Redacted B4> assigned 45 days BUD).

b. Sodium Thiosulfate Anhydi·ous (Sulfur Colloid) Kits, 10mL <Redacted B4>, assigned 45 days BUD).

C. Pentetate Indium Disodium (In-111 DTPA), 3.75mCi (0.50mL) <Redacted B4> and assigned 9 days BUD).

d. Indium Oxyquinoline (In-111 Oxine), 2mCi (1.0mL) <Redacted B4> and assigned 9 days BUD).

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

a. Your firm's Pharmacist stated he conducts <Redacted B4> on the <Redacted B4> but 1s unsure of the specific allowable <Redacted B4> requirement, therefore cannot confnm If the <Redacted B4> This <Redacted B4>is used to render the following nuclear drug injectable products sterile: Pentereotide Kit, 10µg, Metiatide Kit, 1 OmL, PYP Kit, 11.9mg, Exametazime Kit, 0.3mg (Sn-HMPAO), DTPA Kit, 10mg, DMSA Kit, 1.09mg, Sulfur Colloid Kit, 2mg and Tetrafosmin Kit, 0.23mg.

b. On 5/7/19, during the aseptic production of Pyrophosphate Kit, lot #050719PYP, Exp:5/1/2020, your Pharmacist was observed prepping the ingredients within the ISO 5-LAFH (prior to aseptic filling), involving <Redacted B4> of a sterile vial, exited the clean room and entered the ISO-8 anteroom, to weigh the bulk dmg substances, re-entered the clean room and ISO-5 LAFH and began aseptic filling without changing his gloves.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

a. Your Pharmacist stated that Environmental Monitoring (surface and non-viable air) is performed after cleaning and not after production of drug products within the ISO-5 aseptic processing areas therefore providing unreliable results.

b. On 5/6/19, I observed expired <Redacted B4> (exp.: 4/15/19) being used for surface sampling. <Redacted B4> (exp.: 4/21/19) was used previously on Monday, 4/29/19.

C. Your fir m failed to provide sterility assurance of your drug products during the <Redacted B4> On 5/7/19, I observed your firm pouring <Redacted B4> into the <Redacted B4> containing the <Redacted B4> which potentially introduced contamination to the sterile vials prior to the placement into the <Redacted B4> within the ISO-5 LAFH). Cleaning of the interior tubing to the OC <Redacted B4> is not performed. The chamber is only cleaned with <Redacted B4> and your firm has not provided any assurance that this cleaning agent is capable of removing resides from previous <Redacted B4> drug products.

d. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent containination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, on 5/7/19, during the aseptic production of Phosyrophosphate Kit, lot #050719PYP, Exp:5/1/2020:

a. Your firm's ISO 5-LAFH was observed to contain visible signs of rust and deterioration of the working surface.

b. A large <Redacted B4> firm's <Redacted B4> was observed containing blue piping, stained pvc piping, black · aflatable tubing and <Redacted B4> and <Redacted B4> which are difficult to clean and sanitize.

C.

Your Pharmacist was observed using a non-sterilized pipet to fill sterile product within the individual product vials (conducted after <Redacted B4> and non-sterilized <Redacted B4> the vials. The stoppers were <Redacted B4> but the <Redacted B4> minutes) , has not been validated and he was uncertam of the date in which the stoppers were <Redacted B4>

Observation 5

Specifically,

a. Your firm's <Redacted B4> are not validated <Redacted B4> hours at tbH-0' degrees <Redacted B4> as evidenced by the incomplete <Redacted B4> <observed on 5/7/19 for Pyrophosphate Kit, lot #050719PYP, Exp:5/1/2020 (4 out of 11'""vials remained in a <Redacted B4> tate). Your Pharmacist stated this incident has occurred a few times in the past with other drug products and the vials were discarded while the remainder of the lot was shipped. No investigations were ever conducted.

b. On 5/13/19, I observed two colonies (alert level: <Redacted B4> cfu) of growth on the <Redacted B4> (after days of incubation at <Redacted B4> lf degrees Celsius), from the surface sample taken after the completion of the <Redacted B4> for PYP, lot #050719PYP, exp: 5/1/2020. No investigation was conducted.

Observation 6

Results of stability testing are not used in determining appropriate storage conditions and expiration dates.

Specifically, your firm produces the following preservative free nuclear and radiological drug products containing expiration and BUD dating which are not supported through appropriate stability testing: Pentereotide Kits <Redacted B4> and assigned a 1-year expiration), Metatide Kits <Redacted B4> and assigned a I-year expiration), PYP Kits <Redacted B4> and assigned a I-year expiration), Exametazime Kits (Sn-HMPAO) <Redacted B4> and assigned a I-year expiration), DTPA Kits Ki><Redacted B4> and assigned a I-year expiration), Tetrafosmin Kits <Redacted B4> and assigned a I-year expiration), DMSA kits <Redacted B4> assigned 45 days BUD), Sulfur Colloid Kits <Redacted B4> assigned 45 days .an fu-111 DTPA, 3.75mCi <Redacted B4> and assigned 9 days BUD) and fu-111 Oxine, 2mCi and assigned 9 days BUDl.

fu-111 DTPA, 3.75mCi[ b) {4LJ and assigned 9 days BUD) and fu-111 Oxine, 2mCi

and assigned 9 days BUDl.

Observation 7

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance the final specifications and identity and strength of each active ingredient prior to release.

Specifically, your firm failed to conduct potency testing of each active ingredient within your firm's radiological and nuclear drug products: Pentetreotide Kits <Redacted B4> and a signed I-year expiration), Metatide Kits <Redacted B4> and assigned a I-year expiration ), PYP Kits <Redacted B4> and assigned a I-year expiration), Exametazime Kits (Sn-HMPAO) _< Redacted B4> and assist a I-year expiration), DTPA Kits <Redacted B4> and assigned a I-year expiration), Tetrafosmm Kits <Redacted B4> and assigned a I -year expiration ), DMSA lats ~ ] assigned 45 days BUD), Sulfur ColloioKits <Redacted B4> assigned 45 days BUD), In-111 DTPA, 3.75mCi <Redacted B4> and assigned 9 days BUD) and In-111 Oxme, 2mCi <Redacted B4> and assigned 9 days BUD).

Observation 8

Clothing of personnel engaged in the manufacturing, processing, packing and holding of drug products is not appropriate for the duties they perform.

Specifically, on 5/7/19, your firm's Pharmacist was observed donning his non-sterile gown (reusable for one day), non-sterile face mask, sterile boots and bonnet with thefr bru·e hands. This same Pharmacist was observed cleanmg the 1SO-5 LAFH utilizing non-sterile gloves and placing his body, including his head, inside the LAFH.

State board of pharmacy records

State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6902OSPSynthetopes, Inc.Conway, SCVoluntary Surrender

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.